Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"

From Libre Pathology
Jump to navigation Jump to search
Line 15: Line 15:
**Biopsy specimens: solid pattern most common.
**Biopsy specimens: solid pattern most common.
**Resection specimens: acinar pattern most common.
**Resection specimens: acinar pattern most common.
==Images==
==Related images==
<gallery>
Image: Adenocarcinoma - ROS1 positive -- low mag.jpg | NSmCC - low mag.
Image: Adenocarcinoma - ROS1 positive -- intermed mag.jpg | NSmCC - intermed. mag.
Image: Adenocarcinoma - ROS1 positive -- high mag.jpg | NSmCC - high mag.
Image: Adenocarcinoma - ROS1 positive -- very high mag.jpg | NSmCC - very high mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- low mag.jpg | NSmCC - ROS1 - low mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg | NSmCC - ROS1 - intermed. mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- very high mag.jpg | NSmCC - ROS1 -very high mag.
Image: Adenocarcinoma - ROS1 positive - TTF1 -- high mag.jpg | NSmCC - TTF-1 - high mag.
Image: Adenocarcinoma - ROS1 positive - napsin A -- high mag.jpg | NSmCC - napsin A - high mag.
</gallery>


==See also==
==See also==

Revision as of 02:29, 31 December 2019

ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]

General

Microscopic

Features:

  • Histology not definitive; however, predictive features are:[4]

Note:

  • Most common pattern varies by specimen type:[4]
    • Biopsy specimens: solid pattern most common.
    • Resection specimens: acinar pattern most common.

Images

Related images

See also

References

  1. Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  2. "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
  3. "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
  4. 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.